China CAS:439239-92-6 Manufacturer

We insist over the principle of enhancement of 'High high quality, Efficiency, Sincerity and Down-to-earth working approach' to offer you with superb assistance of processing for CAS:439239-92-6, Top quality, timely company and Aggressive cost, all win us a superior fame in xxx field despite the international intense competition.
CAS:439239-92-6, Our company has a skillful sales team, strong economic foundation, great technical force, advanced equipment, complete testing means, and excellent after-sales services. Our goods have beautiful appearance, fine workmanship and superior quality and win the unanimous approvals of the customers all over the world.

Hot Products

  • Methylprednisolone

    Methylprednisolone

    Methylprednisolone has USP, EP, IP, JP and KP specifications. DMF and WC available.

    CAS:83-43-2

  • Fluticasone Furoate

    Fluticasone Furoate

    Fluticasone furoate has In-house specifications. DMF under filing.

    CAS:397864-44-7

  • Mirabegron

    Mirabegron

    Mirabegron has In-house specification. DMF approved..

    CAS:223673-61-8

  • Mifepristone Tablets

    Mifepristone Tablets

    Mifepristone Tablets Specifications:10mg*1
    Indications:Emergency Contraceptive
  • Compound Mifepristone Tablets

    Compound Mifepristone Tablets

    Compound Mifepristone Tablets Specifications:Mifepristone 30mg Anorethidrane 5mg*2
    Indications:Abortion
  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept